Investor Centre

Investor Fact Sheet

$0.07
Open 0.07
High 0.07
Low 0.07
Volume 423,489
Down 0.00
(Down -1.4%
As at 2:18PM 25/05/2022

Investor Fact Sheet

Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products.

Using in house facilities and capabilities, Acrux has successfully developed and has commercialised, through our partners, products into the US, Europe and other international markets.

Acrux’s portfolio of currently marketed FDA approved generic products include Estradiol Solution Spray, Testosterone Topical Solution 30mg/1.5ml and Lidocaine and Prilocaine Cream USP, 2.5%/2.5%. Efinaconazole Solution 10% has been approved by the FDA, with a future launch pending within the terms of the Paragraph IV Settlement Agreement.

The FDA has 2 ANDA Applications currently under regulatory review and 11 further products are in our development pipeline at various stages.

Acrux encourages collaboration and is well positioned to discuss commercial partnering and product development opportunities.

Learn more about Acrux Learn more about our history

Key Corporate Details

Key Corporate Details Incorporated 1998

Acrux is listed on the Australian Stock Exchange (ASX)
ASX Code: ACR

ABN: 72 082 001 152

Registered Office and Principal Business Address:
103-113 Stanley Street, West Melbourne, Victoria, 3003, Australia
Telephone: +61 3837 90100

Website: www.acrux.com.au

Board of Directors

Ross Dobinson - Chair and Non-Executive Director
Michael Kotsanis - Managing Director and Chief Executive Officer
Geoff Brooke - Non-Executive Director
Don Brumley - Non-Executive Director, Chair Audit and Risk Committee
Tim Oldham - Non-Executive Director, Chair Human Capital and Nominations Committee
 

Executive Team

Felicia Colagrande - Product Development and Technical Affairs Director
Mark Hyman - Project and Technical Director
Joanna Johnson - Company Secretary and Chief Financial Officer
Charles O’Sullivan - Portfolio Director

Office

103-113 Stanley Street West Melbourne VIC 3003 Australia
Email: investor@acrux.com.au

Share Registry

Link Market Services
Level 13, Tower 4, 727 Collins Street,
Docklands, Victoria, 3008, Australia


Telephone: +61 1300 554 474 (toll free within Australia)
Email: registrars@linkmarketservices.com.au
Web: www.linkmarketservices.com.au

Auditor

Pitcher Partners
Level 13, 664 Collins Street,
Docklands VIC 3008

Key Events and Dates

 February  Reporting of Half Year Financial Statements
 30 June  Financial Year End
 August  Reporting of Full Year Financial Statements
 September  Closing date for receipt of director nominations before AGM
 November  AGM (1.)
 31 December  Financial Half Year End
 

Details regarding date and location of AGM, as well as business to be dealt with, to be included in Notice of Meeting, announced to ASX and sent to shareholders at least 28 days prior to the meeting.